 Daptomycin
"Daptomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.
| Descriptor ID |
D017576
|
| MeSH Number(s) |
D04.345.566.270 D10.477.500 D12.644.365.500 D12.644.641.270
|
| Concept/Terms |
Cubicin- Cubicin
- Cubist Brand of Injectable Daptomycin
|
Below are MeSH descriptors whose meaning is more general than "Daptomycin".
Below are MeSH descriptors whose meaning is more specific than "Daptomycin".
This graph shows the total number of publications written about "Daptomycin" by people in this website by year, and whether "Daptomycin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 1 | 3 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 2 | 0 | 2 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Daptomycin" by people in Profiles.
-
Santos CAQ, Martinez AI, Won SY, Varughese CA, Tseng M, Zhang H, Trick WE. Computing antimicrobial use/antimicrobial resistance ratios: A novel way to assess inpatient antimicrobial utilization using current National Healthcare Safety Network metrics. Transpl Infect Dis. 2022 Oct; 24(5):e13924.
-
Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013 Dec; 68(12):2921-6.
-
Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013 Sep; 57(9):4190-6.
-
Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011 Jun; 31(6):527-36.
-
Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, Segreti J. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clin Ther. 2010 Sep; 32(10):1713-9.
-
Segreti J. Empirical therapy for serious Gram-positive infections: making the right choice. Clin Microbiol Infect. 2009 Dec; 15 Suppl 6:5-10.
-
Rolston KV, Segreti J, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007 Oct; 120(10 Suppl 1):S4-5.
-
Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy. 2006 Mar; 26(3):347-52.
-
Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin. 2005 Dec; 21(12):1923-6.
-
Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005 Oct; 43(10):5285-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|